Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Hongkong1/2. fázis

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

A legfontosabb adatok

Ki végzi
Institut de Recherches Internationales Servier
Hol
Hong Kong és Shatin (Hongkong)Mind a 2 helyszín megnézéseMég 9 másik országban, 47 helyszínen
Állapot
Toboroz
Fázis
1/2. fázis
Résztvevők
623 fő, tervezett
Kezdés
2023. ápr. 18.
Várható befejezés
2028. jún.
A vizsgálat típusa
Beavatkozással járó, 14 csoport
A vizsgált kezelések
  • S241656
  • FOLFOX6/FOLFOX7
  • FOLFIRI
  • Cetuximab
  • Panitumumab
  • Trametinib
  • Pembrolizumab
A regiszteradat frissítve
2026. november 17.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 33 feltétel megnézéseKevesebb

Ki vehet részt

  • Life expectancy of ≥ 12 weeks in the opinion of the investigator
  • Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations or alterations
  • Adequate bone marrow and organ function
  • Recovered from toxicity to prior anti-cancer therapy; Part 1 Dose Escalation cohort ONLY:
  • Part 1A: Advanced/metastatic NSCLC with KRAS non-G12C, HRAS, NRAS, BRAF or CRAF (RAF1) mutations or alterations
  • Part 1B: Advanced/metastatic GI tumors (e.g., PDAC, CRC, and BTC) with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations
  • Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations
  • Part 1E: Other advanced/metastatic non-GI, non-NSCLC solid tumors with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations
  • Part 1F: Solid tumors with BRAF or NRAS mutations or alterations
  • Part 1G: Solid tumors with BRAF or NRAS mutations or alterations; Part 2 Dose Optimization and Expansion cohorts ONLY:
  • Part 2A: Advanced/metastatic NSCLC with BRAF mutations or alterations
  • Part 2A2: Advanced/metastatic NSCLC with BRAF mutations or alterations
  • Part 2B2: Advanced/metastatic CRC with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations
  • Part 2B3: Advanced/metastatic BTC (adenocarcinoma) with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations
  • Part 2B4: Advanced/metastatic non-CRC GI cancer (adenocarcinoma) with KRAS mutations or alterations
  • Part 2D1: Advanced/metastatic CRC (adenocarcinoma) with BRAF mutations or alterations
  • Part 2F: Advanced/metastatic tumor type with KRAS non-G12C, and/or BRAF mutations or alterations

Ki nem vehet részt

  • Major surgery within 4 weeks of study entry or planned during study
  • Ongoing anticancer therapy
  • Ongoing radiation therapy
  • Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study
  • Prior use of experimental agents that target the KRAS/BRAF/MEK/ERK pathway
  • Part 1G: Active autoimmune disease, severe dermatologic condition, or systemic treatment with corticosteroids
  • Cancer that has a known MEK1/2 mutation
  • Known allergy/hypersensitivity to excipients of S241656 or to any of the registered IMPs administered in combination
  • Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy
  • Clinically significant cardiovascular disease
  • Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years
  • Part 1F: Any ocular abnormality, active myositis or myopathy or history of rhabdomyolysis, or severe dermatologic condition
  • Any contraindication, to the use of any of the combination agents administered as part of the assigned cohort, including failure to meet the regimen-specific ANC requirements
  • Symptomatic spinal cord compression
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO
  • Females who are pregnant or breastfeeding

Ez a vizsgálat jelenleg itt érhető el: Hongkong.

Még 9 másik országban, 47 helyszínen

  • Queen Mary HospitalHong Kong, HongkongContact: Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies DepartmentRésztvevőt keres
  • Prince of WalesShatin, HongkongContact: Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies DepartmentRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. The study population for the Dose Expansion part of the study comprises adults with advanced/metastatic NSCLC, GI tumors (including ColoRectal Cancer (CRC), and non-CRC GI adenocarcinoma, and Biliary Tract Cancer (BTC)) with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28 or 21-days cycles (depending on the study part they are included in) until disease progression, toxicity, withdrawal of consent, or termination of the study.

A vizsgálat 14 csoportja

  • Part 1A: Dose Escalation NSCLCA vizsgált kezelés

    S241656 will be administered as a monotherapy at escalating dose levels until the biologically effective dose (BED) range is determined. This arm is for participants with advanced/metastatic NSCLC harboring KRAS non-G12C, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations, who have received at least one prior line of systemic therapy.

    Kezelés: S241656

  • Part 1B: Dose Escalation GI TumorsA vizsgált kezelés

    S241656 will be administered as a monotherapy at escalating dose levels until the BED range is determined. This arm is for participants with advanced/metastatic GI tumors (PDAC, CRC, BTC, etc.) harboring KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations, who have received at least one prior line of systemic therapy.

    Kezelés: S241656

  • Part 1D: Dose Escalation CRCA vizsgált kezelés

    S241656 will be administered in combination with FOLFOX6/FOLFOX7 or FOLFIRI, and panitumumab or cetuximab at escalating dose levels until the BED range is determined. This arm is for participants with advanced, metastatic CRC with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations.

    Kezelés: S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab és Panitumumab

  • Part 1E: Dose Escalation Other Solid TumorsA vizsgált kezelés

    S241656 will be administered as a monotherapy at escalating dose levels until the BED range is determined. This arm is for participants with other advanced/metastatic non-NSCLC, non-GI solid tumors with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations, who have received at least one prior line of systemic therapy.

    Kezelés: S241656

  • Part 2A: Randomized Dose Optimization NSCLC, first dose levelA vizsgált kezelés

    S241656 will be administered to identify the optimal dose. This arm is for participants with advanced/metastatic BRAF mutated or altered NSCLC.

    Kezelés: S241656

  • Part 2A2: Dose Expansion NSCLC with BRAF mutationsA vizsgált kezelés

    S241656 will be administered as a monotherapy in the BED range. This arm is for participants with advanced/metastatic NSCLC with BRAF mutations or alterations.

    Kezelés: S241656

  • Part 2B2: Dose Expansion CRCA vizsgált kezelés

    S241656 will be administered as a monotherapy in the BED range. This arm is for participants with CRC with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations who have received at least one prior line of therapy

    Kezelés: S241656

  • Part 2B3: Dose Expansion BTCA vizsgált kezelés

    S241656 will be administered as a monotherapy in the BED range. This arm is for participants with BTC with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations who have received at least one prior line of therapy

    Kezelés: S241656

  • Part 2D1: Dose Expansion CRCA vizsgált kezelés

    S241656 will be administered in combination with chemotherapy (FOLFOX6/FOLFOX7 or FOLFIRI) and anti-EGFR antibody (panitumumab or cetuximab) in the BED range. The combination therapies to be used will be determined in the future. This arm is for participants with advanced/metastatic CRC with any class of BRAF mutation or alteration, who are not candidates for surgical resection, have received one prior line of therapy including BRAF-targeted therapy (if applicable and available per local guidelines), and are eligible to receive chemotherapy.

    Kezelés: S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab és Panitumumab

  • Part 2F: Exploratory Food EffectA vizsgált kezelés

    S241656 will be administered as a monotherapy.

    Kezelés: S241656

  • Part 1F: Dose Escalation with Trametinib in Solid TumorsA vizsgált kezelés

    S241656 will be administered in combination with Trametinib at escalating dose levels until the BED range is determined. This arm is for participants with advanced, metastatic solid tumors with BRAF or NRAS mutations or alterations.

    Kezelés: S241656 és Trametinib

  • Part 1G: Dose Escalation with Pembrolizumab in Solid TumorsA vizsgált kezelés

    S241656 will be administered in combination with Pembrolizumab at escalating dose levels until the BED range is determined. This arm is for participants with advanced/metastatic solid tumors harboring BRAF or NRAS mutations or alterations.

    Kezelés: S241656 és Pembrolizumab

  • Part 2B4: Dose Expansion non-CRC GI CancerA vizsgált kezelés

    S241656 will be administered as a monotherapy in the BED range. This arm is for participants with non-CRC GI cancer with KRAS mutations or alterations who must have received at least one prior line of therapy, including or in addition to prior therapy with a pan-RAS inhibitor.

    Kezelés: S241656

  • Part 2A: Randomized Dose Optimization NSCLC, second dose levelA vizsgált kezelés

    S241656 will be administered to identify the optimal dose. This arm is for participants with advanced/metastatic BRAF mutated or altered NSCLC.

    Kezelés: S241656

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
A regiszteradat frissítve
2026. november 17.